Provided is an application of ATPase ATP13A2 in the preparation of biological markers for behavioural and motor abnormalities, the behavioural and motor abnormalities being caused by neural impulse control disorder and dyskinesia, and the amino acid sequence of ATP13A2 being shown in SEQ. No. 1. Also provided is an application for a ceramide-like compound FTY720 or a sphingomyelinase inhibiting compound fluoxetine in the preparation of drugs for the treatment of impulse control behaviour and abnormal motor disease.
IMPULSE CONTROL DISORDER BIOLOGICAL DETECTION MARKER AND PHARMACEUTICAL USE OF IMPULSINS